Overview

Dalfampridine and Gait in Spinocerebellar Ataxias

Status:
Completed

Trial end date:
2013-12-01

Target enrollment:

Participant gender:

Summary

Investigators expect there will be improvement in walking speed and steadiness after taking Dalfampridine, thereby improving activities of daily living and enhancing social and occupational functions for patients with spinocerebellar ataxia.

Phase:

N/A

Details

Lead Sponsor:

University of Florida

Collaborator:

Acorda Therapeutics

Treatments:

4-Aminopyridine